Written by: Andrew Kowalski, PharmD and Osama Abdelghany, PharmD, MHA, BCOP -Smilow Cancer Hospital at Yale New Haven Health
Download Here

There are a number of treatment options for patients with follicular lymphoma that has relapsed or is refractory to first line options. The purpose of this PQI is to discuss appropriate patient identification and clinical considerations around the use of copanlisib for the treatment of adults who have received at least two other previous therapies.

Continue reading Copanlisib (Aliqopa™) for the Management of Relapsed/Refractory Follicular Lymphoma

Read More

Natasha Khrystolubova is one of the lead author of the Journal of Oncology Pharmacy Practice article, Pharmacist-led patient education and adverse event management in patients with non-small cell lung cancer receiving afatinib in a community-based, real-world clinical setting.

An NCODA practice working to make a difference in the pharmacy to positively impact patient care. Florida Cancer Specialists (FCL) have taken an active role in patient care and adherence.

Going Beyond the First Fill gives every patient the monitoring and follow-up to improve care at the pharmacy level through best practices. These are challenges real community-based pharmacies are facing. FCS gives patients the support needed through health education and resources. “The FCS program was designed specifically to manage AEs that occurred during use of afatinib, but many of the principles and approaches could be implemented for patients treated with other types of medication. ” Read More.

Read More

Written by: Jan Montgomery, PharmD, South Carolina Oncology Associates and Jacob Dygert, South University School of Pharmacy
Download Here

To identify appropriate eligible patients for abemaciclib therapy based upon specific prognostic factors.

Continue reading Advanced Breast Cancer: Appropriate Patient Identification with Abemaciclib (Verzenio®)

Read More

Written by: Derek Gyori, PharmD and Julianne Orr, PharmD
Download Here

Abemaciclib is FDA-approved in combination with an aromatase inhibitor, fulvestrant, and as a single agent in metastatic breast cancer. This PQI will address effective practices for the management of abemaciclib associated diarrhea, a common toxicity with this therapy.
Continue reading Management of Abemaciclib (Verzenio®) Associated Diarrhea

Read More

Written By: Chris Sellers, RPh, Texas Oncology
Download Here

The purpose is to provide management of common adverse events, follow-up with patients, and dose modifications. Dose adjustments are common and greatly reduced frequency and severity of adverse reactions. In Lux-Lung 3, 43% maintained the 40mg starting dose, 38% reduced to 30mg and 19% further reduced to 20mg. Progression free survival remained consistent in patients with or without dose adjustments. Continue reading Afatinib (Gilotrif®) Management for Non-Small Cell Lung Cancer

Read More